Special Issue

Antibody Microarrays in Clinical Proteomics

Message from the Guest Editors

High throughput proteomic analysis provides powerful tools for the discovery of novel biomarkers, which could be used in the diagnosis and/or prognosis of diseases. Consequently, protein microarrays have been widely used for profiling biomarkers related with disease development and progression. The advantage of microarrays is that they allow for high throughput screening of large numbers of biomarkers, using minute amount of samples. This special issue will summarize the utilization of antibody microarrays and their implication in clinical settings. The focus will be both on recent technology developments in this field as well as the usefulness of this technique to demonstrate clinical utility and unmet medical needs, such as early diagnosis, patient stratification and evidence therapy selection, Prof.Carl A. K. Borrebaeck

Guest Editors

Prof. Carl A. K. Borrebaeck

Prof. Christer Wingren

Dr. Ulrika Andreasson

Deadline for manuscript submissions

closed (15 September 2015)

Microarrays

an Open Access Journal by MDPI



mdpi.com/si/4178

Microarrays
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microarrays@mdpi.com

mdpi.com/journal/ microarrays



Microarrays

an Open Access Journal by MDPI



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Massimo Negrini
Department of Morphology, Surgery and Experimental Medicine,
University of Ferrara, Ferrara, Italy

Author Benefits

Rapid publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28 days after submission; acceptance to publication is undertaken in 8 days (median values for papers published in this journal in 2016).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

